PDB Short entry for 2LSQ
HEADER    IMMUNE SYSTEM                           04-MAY-12   2LSQ              
TITLE     ANALOG OF THE FRAGMENT 197-221 OF BETA-1 ADRENORECEPTOR               
COMPND    MOL_ID: 1;                                                            
COMPND   2 MOLECULE: ANALOG OF THE FRAGMENT 197-221 OF BETA-1 ADRENORECEPTOR;   
COMPND   3 CHAIN: A;                                                            
COMPND   4 FRAGMENT: EXTRACELLULAR TOPOLOGICAL DOMAIN;                          
COMPND   5 SYNONYM: BETA-1 ADRENORECEPTOR, BETA-1 ADRENOCEPTOR;                 
COMPND   6 ENGINEERED: YES                                                      
SOURCE    MOL_ID: 1;                                                            
SOURCE   2 SYNTHETIC: YES;                                                      
SOURCE   3 ORGANISM_SCIENTIFIC: HOMO SAPIENS;                                   
SOURCE   4 ORGANISM_COMMON: HUMAN;                                              
SOURCE   5 ORGANISM_TAXID: 9606;                                                
SOURCE   6 OTHER_DETAILS: THE PEPTIDE WAS PREPARED BY AUTOMATIC SOLID PHASE     
SOURCE   7 SYNTHESIS (SPPS) USING THE FMOC STRATEGY STARTING FROM 0.25 MMOL OF  
SOURCE   8 COMMERCIAL N FMOC-LYS(BOC)-POLYMER (BACHEM, SWITZERLAND). A          
SOURCE   9 COPOLYMER OF STYRENE WITH 1% DIVINYLBENZENE WITH A                   
SOURCE  10 HYDROXYMETHYLPHENYLOXYMETHYL ANCHORING GROUP (THE WANG-POLYMER) WAS  
SOURCE  11 USED AS A CARRIER. THE SIDE FUNCTIONS OF THE AMINO ACIDS WERE        
SOURCE  12 BLOCKED BY THE FOLLOWING PROTECTIVE GROUPS: BUT FOR HYDROXYL         
SOURCE  13 FUNCTIONS OF SER AND TYR; BUT FOR CARBOXYL FUNCTIONS OF ASP AND GLU; 
SOURCE  14 BOC FOR -AMINO FUNCTIONS OF LYS; TRT FOR CARBOXYLAMIDE GROUP OF ASN, 
SOURCE  15 SULFHYDRYL FUNCTIONS OF RESIDUES CYS198 AND CYS220; ACM FOR          
SOURCE  16 SULFHYDRYL FUNCTIONS OF RESIDUES CYS209 AND CYS215, AND PBF FOR      
SOURCE  17 GUANIDINE FUNCTION OF ARG. THE AMINO ACID CHAIN WAS ELONGATED        
SOURCE  18 STEPWISE STARTING FROM C-TERMINUS USING CARBODIIMIDE IN THE PRESENCE 
SOURCE  19 OF 1-HYDROXYBENZOTRIASOLE. WHEN THE SPPS WAS FINISHED, THE PEPTIDE   
SOURCE  20 WAS CLEAVED FROM CARRIER WITH THE SIMULTANEOUS REMOVAL OF THE ACID-  
SOURCE  21 LABILE PROTECTIVE GROUPS BY TREATMENT WITH TRIFLUORACETIC ACID WITH  
SOURCE  22 THE ADDITION OF WATER, TRIISOPROPYLSILANE AND DITHIOTHREITOLE. THE   
SOURCE  23 SYNTHESIZED [CYS(ACM)2]PEPTIDE WAS PURIFIED BY HPLC TO A PURITY 85-  
SOURCE  24 90%. THE INTRAMOLECULAR S-S BRIDGE BETWEEN CYS198 AND CYS220 WAS     
SOURCE  25 WITH HYDROGEN PEROXIDE AT PH 8. THE TARGET MONOCYCLIC INTERMEDIATE   
SOURCE  26 OF PEPTIDE WAS PURIFIED BY HPLC TO A PURITY 90-95%. THE PRODUCT WAS  
SOURCE  27 CHARACTERIZED BY MALDI-TOF MASS SPECTROMETRY. THE SECOND DISULFIDE   
SOURCE  28 BOND BETWEEN CYS209 AND CYS215 WAS FORMED BY THE TREATMENT OF        
SOURCE  29 MONOCYCLIC INTERMEDIATE [CYS(ACM)2]PEPTIDE WITH IODINE (FOR          
SOURCE  30 SIMULTANEOUS CLEAVAGE OF ACM GROUP AND FORMATION S-S BRIDGE) IN      
SOURCE  31 METHANOL. THE BICYCLIC TARGET PRODUCT WAS PURIFIED BY HPLC TO A      
SOURCE  32 PURITY 98% AND CHARACTERIZED BY MALDI-TOF MASS SPECTROMETRY.         
KEYWDS    BETA1-ADRENORECEPTOR, MODIFIED EXTRACELLULAR LOOP 197-221,            
KEYWDS   2 AUTOANTIBODIES, CARDIOMYOPATHY, ARRHYTHMIA, IMMUNE SYSTEM            
EXPDTA    SOLUTION NMR                                                          
NUMMDL    20                                                                    
AUTHOR    V.N.BUSHUEV,K.A.ZYKOV,Z.D.BESPALOVA,R.S.BIBILASHVILI,E.E.EFREMOV,     
AUTHOR   2 S.P.GOLITSYN,L.I.KAZNACHEEVA,T.V.KUZHETSOVA,P.S.LEVASHOV,            
AUTHOR   3 V.P.MASENKO,N.A.MIRONOVA,F.S.MOLOKOEDOV,P.N.RUTKEVICH,A.V.RVACHEVA,  
AUTHOR   4 T.V.SHARF,M.V.SIDOROVA,T.N.VLASIK,E.V.YANUSHEVSKAYA                  
REVDAT   1   08-MAY-13 2LSQ    0                                                
JRNL        AUTH   V.N.BUSHUEV                                                  
JRNL        TITL   ANALOG OF THE FRAGMENT 197-221 OF 1-ADRENORECEPTOR           
JRNL        REF    TO BE PUBLISHED                                              
JRNL        REFN                                                                
REMARK   2                                                                      
REMARK   2 RESOLUTION. NOT APPLICABLE.                                          
REMARK   3                                                                      
REMARK   3 REFINEMENT.                                                          
REMARK   3   PROGRAM     : CYANA                                                
REMARK   3   AUTHORS     : GUNTERT, MUMENTHALER AND WUTHRICH                    
REMARK   3                                                                      
REMARK   3  OTHER REFINEMENT REMARKS: NULL                                      
REMARK   4                                                                      
REMARK   4 2LSQ COMPLIES WITH FORMAT V. 3.30, 13-JUL-11                         
REMARK 100                                                                      
REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 07-MAY-12.                  
REMARK 100 THE RCSB ID CODE IS RCSB102786.                                      
REMARK 210                                                                      
REMARK 210 EXPERIMENTAL DETAILS                                                 
REMARK 210  EXPERIMENT TYPE                : NMR                                
REMARK 210  TEMPERATURE           (KELVIN) : 303                                
REMARK 210  PH                             : 5.5                                
REMARK 210  IONIC STRENGTH                 : 22                                 
REMARK 210  PRESSURE                       : AMBIENT                            
REMARK 210  SAMPLE CONTENTS                : 2 MM PROTEIN, 1 MM SODIUM AZIDE,   
REMARK 210                                   20 MM [U-100% 2H] SODIUM ACETATE,  
REMARK 210                                   90% H2O/10% D2O; 2 MM PROTEIN, 1   
REMARK 210                                   MM SODIUM AZIDE, 20 MM [U-100%     
REMARK 210                                   2H] SODIUM ACETATE, 100% D2O       
REMARK 210                                                                      
REMARK 210  NMR EXPERIMENTS CONDUCTED      : 2D 1H-13C HSQC ALIPHATIC; 2D 1H-   
REMARK 210                                   13C HSQC AROMATIC; 2D DQF-COSY;    
REMARK 210                                   2D 1H-1H NOESY; 2D 1H-1H TOCSY     
REMARK 210  SPECTROMETER FIELD STRENGTH    : 500 MHZ                            
REMARK 210  SPECTROMETER MODEL             : DPX                                
REMARK 210  SPECTROMETER MANUFACTURER      : BRUKER                             
REMARK 210                                                                      
REMARK 210  STRUCTURE DETERMINATION.                                            
REMARK 210   SOFTWARE USED                 : XWINNMR 1.3, CARA 1.9.5, CYANA     
REMARK 210                                   3.0                                
REMARK 210   METHOD USED                   : TORSION ANGLE DYNAMICS             
REMARK 210                                                                      
REMARK 210 CONFORMERS, NUMBER CALCULATED   : 100                                
REMARK 210 CONFORMERS, NUMBER SUBMITTED    : 20                                 
REMARK 210 CONFORMERS, SELECTION CRITERIA  : TARGET FUNCTION                    
REMARK 210                                                                      
REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1                   
REMARK 210                                                                      
REMARK 210 REMARK: NULL                                                         
REMARK 215                                                                      
REMARK 215 NMR STUDY                                                            
REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION           
REMARK 215 NMR DATA.  PROTEIN DATA BANK CONVENTIONS REQUIRE THAT                
REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON              
REMARK 215 THESE RECORDS ARE MEANINGLESS.                                       
REMARK 300                                                                      
REMARK 300 BIOMOLECULE: 1                                                       
REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM                
REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN                  
REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON               
REMARK 300 BURIED SURFACE AREA.                                                 
REMARK 350                                                                      
REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN           
REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE                
REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS          
REMARK 350 GIVEN BELOW.  BOTH NON-CRYSTALLOGRAPHIC AND                          
REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN.                               
REMARK 350                                                                      
REMARK 350 BIOMOLECULE: 1                                                       
REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC                         
REMARK 350 APPLY THE FOLLOWING TO CHAINS: A                                     
REMARK 350   BIOMT1   1  1.000000  0.000000  0.000000        0.00000            
REMARK 350   BIOMT2   1  0.000000  1.000000  0.000000        0.00000            
REMARK 350   BIOMT3   1  0.000000  0.000000  1.000000        0.00000            
REMARK 500                                                                      
REMARK 500 GEOMETRY AND STEREOCHEMISTRY                                         
REMARK 500 SUBTOPIC: TORSION ANGLES                                             
REMARK 500                                                                      
REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS:            
REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER;               
REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE).                             
REMARK 500                                                                      
REMARK 500 STANDARD TABLE:                                                      
REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2)                    
REMARK 500                                                                      
REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI-           
REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400            
REMARK 500                                                                      
REMARK 500  M RES CSSEQI        PSI       PHI                                   
REMARK 500  1 TRP A   3     -165.52    -74.27                                   
REMARK 500  1 ALA A   5       35.66    -87.29                                   
REMARK 500  1 GLU A   6       13.36   -141.97                                   
REMARK 500  1 CYS A  19       47.29   -153.77                                   
REMARK 500  1 ASP A  21     -164.52    -61.46                                   
REMARK 500  2 TRP A   3     -165.53    -74.67                                   
REMARK 500  2 GLU A   6       15.44   -146.27                                   
REMARK 500  2 ASN A  15       38.30    -95.94                                   
REMARK 500  2 CYS A  19       46.90   -152.85                                   
REMARK 500  2 ASP A  21     -164.13    -61.28                                   
REMARK 500  3 TRP A   3     -167.75    -74.53                                   
REMARK 500  3 GLU A   6       14.76   -142.12                                   
REMARK 500  3 CYS A  19       47.34   -153.89                                   
REMARK 500  3 ASP A  21     -164.18    -61.62                                   
REMARK 500  3 CYS A  24     -174.81    -63.86                                   
REMARK 500  4 TRP A   3     -167.52    -74.77                                   
REMARK 500  4 GLU A   6       14.98   -144.28                                   
REMARK 500  4 ASN A  15       35.16    -98.88                                   
REMARK 500  4 CYS A  19       47.07   -153.48                                   
REMARK 500  4 ASP A  21     -164.15    -61.69                                   
REMARK 500  4 CYS A  24     -175.10    -63.82                                   
REMARK 500  5 TRP A   3     -165.46    -74.25                                   
REMARK 500  5 ALA A   5       35.43    -87.66                                   
REMARK 500  5 GLU A   6       12.74   -141.80                                   
REMARK 500  5 ASN A  15       38.36    -98.73                                   
REMARK 500  5 CYS A  19       46.98   -153.07                                   
REMARK 500  5 ASP A  21     -163.71    -61.23                                   
REMARK 500  6 TRP A   3     -165.65    -74.80                                   
REMARK 500  6 ALA A   5       31.71    -88.38                                   
REMARK 500  6 GLU A   6       14.39   -141.69                                   
REMARK 500  6 ASN A  15       35.66    -98.78                                   
REMARK 500  6 CYS A  19       47.22   -153.72                                   
REMARK 500  6 ASP A  21     -164.49    -61.46                                   
REMARK 500  7 ALA A   5       39.11    -85.92                                   
REMARK 500  7 GLU A   6       12.93   -142.05                                   
REMARK 500  7 ASN A  15       38.00    -96.60                                   
REMARK 500  7 CYS A  19       46.90   -152.73                                   
REMARK 500  7 ASP A  21     -164.02    -61.60                                   
REMARK 500  8 TRP A   3     -165.53    -74.67                                   
REMARK 500  8 ALA A   5       36.71    -87.88                                   
REMARK 500  8 GLU A   6       13.76   -143.71                                   
REMARK 500  8 CYS A  19       47.41   -154.08                                   
REMARK 500  8 ASP A  21     -164.07    -61.61                                   
REMARK 500  9 ALA A   5       41.14    -86.03                                   
REMARK 500  9 GLU A   6       13.51   -143.98                                   
REMARK 500  9 CYS A  19       46.91   -153.08                                   
REMARK 500  9 ASP A  21     -164.18    -61.47                                   
REMARK 500 10 TRP A   3     -168.26    -74.55                                   
REMARK 500 10 GLU A   6       15.89   -143.85                                   
REMARK 500 10 ASN A  15       36.87    -98.66                                   
REMARK 500                                                                      
REMARK 500 THIS ENTRY HAS     100 RAMACHANDRAN OUTLIERS.                        
REMARK 500                                                                      
REMARK 500 REMARK: NULL                                                         
REMARK 900                                                                      
REMARK 900 RELATED ENTRIES                                                      
REMARK 900 RELATED ID: 18440   RELATED DB: BMRB                                 
REMARK 999                                                                      
REMARK 999 SEQUENCE                                                             
REMARK 999 AUTHORS STATE THAT THIS IS AN ANALOG OF THE FRAGMENT 197-221 OF      
REMARK 999 BETA-1 ADRENORECEPTOR.                                               
DBREF  2LSQ A    1    25  UNP    P08588   ADRB1_HUMAN    197    221             
SEQADV 2LSQ ASN A    1  UNP  P08588    HIS   197 SEE REMARK 999                 
SEQADV 2LSQ CYS A    2  UNP  P08588    TRP   198 SEE REMARK 999                 
SEQADV 2LSQ SER A   20  UNP  P08588    CYS   216 SEE REMARK 999                 
SEQADV 2LSQ SER A   22  UNP  P08588    PHE   218 SEE REMARK 999                 
SEQADV 2LSQ CYS A   24  UNP  P08588    THR   220 SEE REMARK 999                 
SEQADV 2LSQ LYS A   25  UNP  P08588    ASN   221 SEE REMARK 999                 
SEQRES   1 A   25  ASN CYS TRP ARG ALA GLU SER ASP GLU ALA ARG ARG CYS          
SEQRES   2 A   25  TYR ASN ASP PRO LYS CYS SER ASP SER VAL CYS LYS              
HELIX    1   1 ASP A    8  CYS A   13  1                                   6    
HELIX    2   2 TYR A   14  SER A   20  5                                   7    
SSBOND   1 CYS A    2    CYS A   24                          1555   1555  2.11  
SSBOND   2 CYS A   13    CYS A   19                          1555   1555  2.11  
CRYST1    1.000    1.000    1.000  90.00  90.00  90.00 P 1           1          
ORIGX1      1.000000  0.000000  0.000000        0.00000                         
ORIGX2      0.000000  1.000000  0.000000        0.00000                         
ORIGX3      0.000000  0.000000  1.000000        0.00000                         
SCALE1      1.000000  0.000000  0.000000        0.00000                         
SCALE2      0.000000  1.000000  0.000000        0.00000                         
SCALE3      0.000000  0.000000  1.000000        0.00000